|
|
The 1st World Congress on
Controversies in Hematology (COHEM)
Rome, Italy, 2-5 September, 2010 |
|
| |
| Preliminary Scientific Program_old |
 |
|
|
|
Thursday, September 2, 2010 |
|
19:00-21:00 |
WELCOME RECEPTION |
|
Friday, September 3, 2010 |
| Session 1 |
PLENARY SESSION |
| 08:30-10:00 |
|
| Debate: |
Did we substantially improve MDS therapy in the last decade? |
|
Moderator: E. Rachmilewitz, Israel |
|
Yes: H. Kantarjian, USA |
|
No: C. Schiffer, USA |
| Debate: |
Is there a role for SCT in Multiple Myeloma? |
|
Moderator: N. Kröger, Germany |
|
Yes: B. Barlogie, USA |
|
No: M. Boccadoro, Italy |
| Session 2 |
ACUTE MYELOID LEUKEMIA (AML) I
|
| 10:30-12:30 |
|
| Debate: |
About targeted therapies in AML: Have standard treatments reached their limits? |
|
Moderator: S. Amadori, Italy |
|
Yes: A. Burnett, UK |
|
No: B. Löwenberg, The Netherlands |
| Debate: |
Should the therapy of AML be driven by MRD quantification? |
|
Moderator: B. Löwenberg, The Netherlands |
|
Yes: S. Amadori, Italy |
|
No : C. Schiffer, USA |
|
Session 3 |
ACUTE MYELOID LEUKEMIA (AML) II and
ACUTE PROMYELOCYTIC LEUKEMIA (APL)
|
|
14:30-16:30 |
|
|
Debate: |
Do we require chemotherapy to cure APL? |
|
|
Moderator: A. Burnett, UK |
|
|
Yes: M.A. Sanz, Spain |
|
|
No: F. Lo-Coco, Italy |
| Debate: |
Can novel prognostic markers predict for success and guide therapy in AML? |
|
Moderator: C. Schiffer, USA |
|
Yes: D. Grimwade, UK |
|
No: A. Burnett, UK |
|
Session 4 |
ACUTE LYMPHATIC LEUKEMIA (ALL) |
|
17:00-19:00 |
|
|
Debate: |
Is the efficacy of the pediatric-like protocols for ALL superior to the protocols for adult ALL? |
|
|
Moderator: R. Foà, Italy |
|
|
Yes: J.P. Marie, France |
|
|
No: J. Ribera, Spain |
| Debate: |
Should the induction for Ph+ ALL be based on TKI alone or TKI plus chemotherapy? |
|
Moderator: J.P. Marie, France |
|
TKI Alone: R. Foà, Italy |
|
TKI plus chemotherapy: O. Ottmann, Germany |
|
Session 5 |
CHRONIC LYMPHATIC LEUKEMIA (CLL) |
|
10:30-12:30 |
|
| Debate: |
Is eradication of MRD feasible and worthwhile in CLL? |
|
Moderator: K. Rai, USA |
|
Yes: G. Marti, USA |
|
No: G. Gaidano, Italy |
|
Debate: |
Is the “wait and watch” philosophy still practical in the treatment of CLL even in younger patients? |
|
|
Moderator: A. Polliack, Israel |
|
|
Yes: K. Rai, USA |
|
|
No: F. Caligaris-Cappio, Italy |
| Session 6 |
INDOLENT NON-HODGKIN’S LYMPHOMAS (NHL) |
| 14:30-16:30 |
|
| Debate: |
Is there a role for Rituximab in maintenance treatment in non-follicular indolent lymphomas? |
|
Moderator: C. Portlock, USA |
|
Yes: A. Hagenbeek, The Netherlands |
|
No: C. Buske, Germany |
| Debate: |
Is molecular remission the goal in first line therapy of all patients with indolent non-Hodgkin lymphoma? |
|
Moderator: A. Hagenbeek, The Netherlands |
|
Yes: P. Corradini, Italy |
|
No: C. Tarella, Italy |
|
Session 7 |
MULTIPLE MYELOMA (MM) |
|
17:00-19:00 |
|
| Debate: |
Multiple Myeloma in patients <70 years: Cure vs. Disease Control |
|
Moderator: M. Boccadoro, Italy |
|
Cure: J.F. San-Miguel, Spain |
|
Control: A. Palumbo, Italy |
| Debate: |
Should Therapy for newly diagnosed MM be risk adapted? |
|
Moderator: A. Palumbo, Italy |
|
Yes: M. Attal, France |
|
No: E. Terpos, Greece |
|
Saturday, September 4, 2010 |
|
Session 8 |
STEM CELL TRANSPLANATION (SCT) I |
|
08:30-10:00 |
The role of Allogeneic SCT (AlloSCT) in Hematological Malignancies |
|
Debate: |
How should we treat a 60 year old patient with Myelodysplastic syndrome? |
|
|
Moderator: M. Martelli, Italy |
|
|
AlloSCT: N. Kröger, Germany |
|
|
Conventional Therapy: U. Platzbecker, Germany |
|
Debate: |
Should all adult ALL patients have a stem cell transplantation in first remission or only high risk patients? |
|
|
Moderator: W. Arcese, Italy |
|
|
All: A. Goldstone, UK |
|
|
Only high risk: D. Hoelzer, Germany |
| Session 9 |
STEM CELL TRANSPLANATION (SCT) II |
| 10:30-12:30 |
Alternative Donor and Reduced Intensity Conditioning (RIC) AlloSCT |
| Debate: |
Should CBT, Haploidentical transplant or MUD transplant be considered upfront if no sibling donor is available? |
|
Moderator: A. Rambaldi, Italy |
|
CBT: W. Arcese, Italy |
|
Haplo: M. Martelli, Italy |
|
MUD: A. Bacigalupo, Italy |
| Debate: |
Should we use AlloSCT in Acute Myeloid Leukemia RIC or Myeloablative preparative protocols? |
|
Moderator: A. Bacigalupo, Italy |
|
RIC: A. Nagler, Israel |
|
Myeloablative: A. Rambaldi, Italy |
| Session 10 |
MDS |
| 14:30-16:30 |
|
| Debate: |
Do hypomethylating agents improve survival in patients with high risk myelodysplastic syndromes? |
|
Moderator: G. Leone, Italy |
|
Yes: V. Santini, Italy |
|
No: M. Cazzola, Italy |
| Debate: |
Is there a rationale for iron chelation therapy in MDS? |
|
Moderator: E. Rachmilewitz, Israel |
|
Yes: N. Gattermann, Germany |
|
No: A. Tefferi, USA |
|
Session 11 |
HODGKIN AND NON-HODGKIN LYMPHOMAS |
|
17:00-19:00 |
|
| Debate: |
Has PET/CT an established role in the management of HD and NHLs? |
|
Moderator: M. Björkholm, Sweden |
|
Yes: M. Hutchings, Denmark |
|
No: U. Vitolo, Italy |
| Debate: |
Does molecular outcome prediction in DLBCL add clinical value? |
|
Moderator: M. Björkholm, Sweden |
|
Yes: C. Gisselbrecht, France |
|
No: M. Pfreundschuh, Germany |
| Session 12 |
CHRONIC MYELOID LEUKEMIA (CML) I |
| 08:30-10:00 |
|
| Debate: |
Will second generation TKIs substitute imatinib as first line treatment of CML? |
|
Moderator: R. Hehlmann, Germany |
|
Yes: M. Baccarani, Italy |
|
No: H. Kantarjian, USA |
| Debate: |
Can we eventually stop TKI in all CML patients? |
|
Moderator: M. Baccarani, Italy |
|
Yes: F. Mahon, France |
|
No: J. Goldman, UK |
| Session 13 |
CHRONIC MYELOID LEUKEMIA (CML) II |
| 10:30-12:30 |
|
| Debate: |
Is mutation analysis of BCR ABL of any value in clinical management of CML patients? |
|
Moderator: J. Goldman, UK |
|
Yes: A. Hochhaus, Germany |
|
No: D. Marin, UK |
|
Debate: |
Should first line imatinib treatment be optimized by combination with IFN or by higher imatinib dose? |
|
|
Moderator: A. Hochhaus, Germany |
|
|
Combination with IFN: F. Guilhot, France |
|
|
Higher initial imatinib dose: R. Hehlmann, Germany |
| Debate: |
On the road to cure CML, does it matter to hit different pathways? |
|
Moderator: |
|
Yes: F. Giles, USA |
|
No: |
| Session 14 |
COAGULATION |
| 14:30-16:30 |
|
|
Debate: |
Are there indications for thrombophylaxis in cancer patients during and after chemotherapy? |
|
Moderator: M.M. Samama, France |
|
|
Yes: A. Falanga, Italy |
|
|
No: A. Kakkar, UK |
| Debate: |
Is there still a role for splenectomy in ITP? |
|
Moderator: A. Falanga, Italy |
|
Yes: B. Godeau, France |
|
No: J. Bussel, USA |
| Session 15 |
HEMOGLOBINOPATHIES & PNH |
| 17:00-19:00 |
|
|
Lecture: |
Pros and cons of gene therapy in beta-thalassemia |
|
Moderator: L. Luzzatto, Italy |
|
|
Lecture: S. Rivella, USA |
|
Lecture: |
The controversies in the use of chelating drugs for the treatment of iron overload affect the morbidity and mortality of thalassaemia and other transfused patients worldwide |
|
|
Moderator: E. Rachmilewitz, Israel |
|
|
Lecture: G. Kontoghiorghes, Cyprus |
| Debate: |
How far one should go with iron chelation in thalassemia? Is iron deficiency indicated? |
|
Moderator: E. Rachmilewitz, Israel |
|
Yes: V. Berdoukas, Greece |
|
No: M.D. Cappellini, Italy |
| Debate: |
Do the benefits of complement blockade extend to all patients with PNH clone? |
|
Moderator: |
|
Yes: J. Maciejewski, USA |
|
No: L. Luzzatto, Italy |
|
Sunday, September 5, 2010 |
| Session 16 |
MYELO PROLIFERATIVE NEOPLAMS (MPNs) |
| 08:30-10:00 |
|
|
Debate: |
Are JAK2 positive PV, ET and IM different diseases? |
|
|
Moderator: A. Tefferi, USA |
|
|
Yes: W. Vainchenker, France |
|
|
No: A.M. Vannucchi, Italy |
| Debate: |
Do JAK2 inhibitors represent a major advance in the treatment of myeloproliferative neoplasms? |
|
Moderator: W. Vainchenker, France |
|
Yes: A. Tefferi, USA |
|
No: T. Barbui, Italy |
|
Session 17 |
INFECTIONS |
|
08:30-10:00 |
|
|
Debate: |
Is there a role for empirical or pre-emptive antifungal treatment in patients with hematological malignancies? |
|
|
Moderator: F. Menichetti, Italy |
|
|
Yes: B. de Pauw, The Netherlands |
|
|
No: A. Prentice, UK |
|
Debate: |
Is monitoring of azole concentrations of clinical value in pts with hematological malignancies? |
|
|
Moderator: B. de Pauw, The Netherlands |
|
|
Yes: F. Menichetti, Italy |
|
|
No: P. Donnelly, The Netherlands |
| Session 18 |
PLENARY SESSION |
| 10:30-13:00 |
|
| Debate: |
Is there a role of biologic prognostic markers in the treatment of CLL? |
|
Moderator: E. Rachmilewitz, Israel |
|
For: R. Foà, Italy |
|
Against: K. Rai, USA |
| Debate: |
Are there sufficient indications for switching to new anticoagulant agents? |
|
Moderator: G. Saglio, Italy |
|
For: M.M Samama, France |
|
Against: A. Falanga, Italy |
| Debate: |
Which is the best chemotherapy regimen in Hodgkin’s Lymphoma? |
|
Moderator: D. Straus, USA |
|
ABVD: A. Levis, Italy |
|
BEACOPP: V. Diehl, Germany |
| Lecture: |
Is chemotherapy alone sufficient for the treatment of Hodgkin's Lymphoma? |
|
Lecture: D. Straus, USA |
|
|
|
|
|
|
|
|
WebStudio.co.il